EHP-102 is being developed as an oral pharmaceutical product candidate for the treatment of various neurodegenerative diseases. The novel API in EHP-102 (VCE-003.2) has been modified to provide positive effects by positively affecting PPARγ, a key molecular target for the treatment of Huntington’s disease (HD) and Parkinson’s disease (PD), as well as other pathways involved in the pathophysiology of neurodegenerative diseases. These characteristics have led EHP to develop this proprietary new drug candidate initially for HD and PD.
The API (VCE-003.2) in our second product candidate (EHP-102) has been shown to affect PPARγ, like EHP-101. Unlike EHP-101, however, it does not affect CB2 receptors or the HIF pathway, but has been shown to activate a transcription factor involved in nerve cell differentiation (the chicken ovalbumin upstream promoter transcription factor-interacting protein, CTIP2). It also reduces the expression of cyclooxygenase-2 (COX-2) in nerve cells (involved in inflammation and pain) and is an activator of the extracellular signal-regulated kinases (ERK) pathway (a member of the mitogen-activated protein kinases [MAPK] pathway) in hippocampal neuronal progenitor cells.
This combined MoA provides for reduced neuroinflammation, increased neuroprotection and the potential for neurogenesis (the regeneration of new nerve cells) as shown here:
In preclinical studies to date, EHP-102 has demonstrated the potential to promote the regeneration of nerve cells, protect against neuroinflammation and neurodegeneration in Huntington’s disease and reduce the loss of dopamine production in Parkinson’s disease. These data support EHP-102’s potential to be disease-modifying rather than only symptomatic, thus possibly providing a beneficial treatment option for these complex diseases with no cure.